A promising medication , retatrutide, is generating considerable buzz in the field of weight reduction. This new therapy, a dual -action receptor agonist, appears to influence both GLP-1 and GIP hormones, potentially leading to significant decreases in body mass and enhancing metabolic function . Early research tests have indicated impressive outco